ABSTRACT
Ultraviolet light B (UVB) is one of the oldest therapeutic modalities for the treatment of psoriasis. Because of its long track record of both safety and efficacy, UVB phototherapy continues to enjoy widespread use in spite of the development of many newer modalities for treating psoriasis, including psoralen and ultraviolet A (PUVA) therapy and various systemic agents. Certain forms of UVB phototherapy, such as the traditional Goeckerman regimen, induce a prolonged remission according to available published data; indeed, Goeckerman treatment is often used as the gold standard against which newer modalities are compared in terms of remission times (1).
